mTOR inhibitor use in head and neck squamous cell carcinoma: A meta‐analysis on survival, tumor response, and toxicity
Abstract Background Head and neck squamous cell carcinoma (HNSCC) has been rising in incidence primarily related to HPV‐associated oropharyngeal cancers. Novel molecular therapeutics are evolving with the mTOR pathway as a new target. Previous studies have shown variable outcomes with relatively low...
Main Authors: | Jaimin Patel, Shaun A. Nguyen, Besim Ogretmen, Jorge S. Gutkind, Cherie‐Ann Nathan, Terry Day |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-04-01
|
Series: | Laryngoscope Investigative Otolaryngology |
Subjects: | |
Online Access: | https://doi.org/10.1002/lio2.370 |
Similar Items
-
De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers—HPV and Beyond
by: Alexander Rühle, et al.
Published: (2021-05-01) -
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)
by: Kedar Kirtane, et al.
Published: (2018-12-01) -
Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
by: Ming-Huei Chou, et al.
Published: (2021-03-01) -
mTOR Signalling in Head and Neck Cancer: Heads Up
by: Fiona H. Tan, et al.
Published: (2019-04-01) -
The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020
by: Flora Yan, et al.
Published: (2020-06-01)